FZD2: Frizzled-2
Receptor for Wnt proteins.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on FZD2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vantictumab | Phase 2 | OncoMed Pharmaceuticals | Antibody | AntagonistFrizzled-2 antagonist | 0 |
- Autosomal dominant omodysplasia0.74
- Robinow syndrome0.62
- Autosomal dominant Robinow syndrome0.60
- Omodysplasia0.46
- Short stature0.29
- Sensorineural hearing loss disorder0.20
- Ovarian carcinoma0.14
- High grade ovarian serous adenocarcinoma0.12
- Keratoconus0.11
- Breast cancer0.11
- Amelogenesis imperfecta0.10
- Neoplasm0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559686, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q14332, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets